Abstract
Transfusion-related (TR)- acute lung injury (ALI) is the leading cause of transfusion-related morbidity and mortality. The pathogenesis of TRALI is thought to be a “two hit”-entity: the “first hit” is (any) proinflammatory pulmonary condition (e.g., pneumonia, sepsis or lung contusion) resulting in activation of lung endothelium with sequestration of polymorphonuclear neutrophils - the “second hit” is provided by transfusion of a blood product. Either antibodies against neutrophils are thought to be implicated in the activation of the sequestrated neutrophils, or bioactive lipids (which accumulate during storage of blood products) induce the “second hit”, finally resulting in lung injury. Preventive measures do not prevent all TRALI cases. Also, TRALI is most probably underdiagnosed. In this review, we call for the development of therapeutic approaches for this potentially life-threatening disease. Several interventions which are beneficial in ALI and may also be beneficial in TRALI are discussed. The application of these interventions requires the development of clinically relevant TRALI animal models. We discuss the present TRALI animal models and their shortcomings and propose future animal models, in which clinically relevant “first hits” can be applied, thereby imitating the complex clinical situation.
Keywords: TRALI, transfusion, acute lung injury, animal models, lysophosphocholines, HLA, HNA
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Developing Specific Therapeutic Strategies for Transfusion-Related Acute Lung Injury. An Overview of Potentially Useful Animal Models
Volume: 5 Issue: 4
Author(s): Alexander P.J. Vlaar, Machteld M. Zweers, Marcus J. Schultz and Nicole P. Juffermans
Affiliation:
Keywords: TRALI, transfusion, acute lung injury, animal models, lysophosphocholines, HLA, HNA
Abstract: Transfusion-related (TR)- acute lung injury (ALI) is the leading cause of transfusion-related morbidity and mortality. The pathogenesis of TRALI is thought to be a “two hit”-entity: the “first hit” is (any) proinflammatory pulmonary condition (e.g., pneumonia, sepsis or lung contusion) resulting in activation of lung endothelium with sequestration of polymorphonuclear neutrophils - the “second hit” is provided by transfusion of a blood product. Either antibodies against neutrophils are thought to be implicated in the activation of the sequestrated neutrophils, or bioactive lipids (which accumulate during storage of blood products) induce the “second hit”, finally resulting in lung injury. Preventive measures do not prevent all TRALI cases. Also, TRALI is most probably underdiagnosed. In this review, we call for the development of therapeutic approaches for this potentially life-threatening disease. Several interventions which are beneficial in ALI and may also be beneficial in TRALI are discussed. The application of these interventions requires the development of clinically relevant TRALI animal models. We discuss the present TRALI animal models and their shortcomings and propose future animal models, in which clinically relevant “first hits” can be applied, thereby imitating the complex clinical situation.
Export Options
About this article
Cite this article as:
Vlaar P.J. Alexander, Zweers M. Machteld, Schultz J. Marcus and Juffermans P. Nicole, Developing Specific Therapeutic Strategies for Transfusion-Related Acute Lung Injury. An Overview of Potentially Useful Animal Models, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (4) . https://dx.doi.org/10.2174/187152507782109845
DOI https://dx.doi.org/10.2174/187152507782109845 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection
Recent Patents on Anti-Infective Drug Discovery Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials
Current Drug Targets Hydroxyimine NO-Donors; FK409 and Derivatives
Current Topics in Medicinal Chemistry Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies
Current Drug Targets Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology PEDF and Septic Shock
Current Molecular Medicine Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design